Whalegun
Lobbying

Primus Pharmaceutical's latest lobbying report covers Q2 2026, at under $5,000. Its first report covers Q4 2022; the issues it reports most are Health Issues.

Primus Pharmaceutical

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$0
Last 4 quarters
vs last quarter
No record
Q3 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

Primus Pharmaceutical lobbying by quarter
Primus Pharmaceutical lobbying by quarter
QuarterAmountReports
Q4 2022$30K1
Q1 2023$30K1
Q2 2023$30K1
Q3 2023$30K1
Q4 2023$30K1
Q1 2024$01
Q2 2024$01
Q3 2024$01
Q4 2024$01
Q1 2025$01
Q2 2025$01
Q3 2025$01
Q4 2025$01
Q1 2026$01
Q2 2026$01
Q3 2026$00

By issue

  • Health issues$150K · 15 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • HOUSE OF REPRESENTATIVES15 reports
  • SENATE15 reports

Firms it paid

Firm
Upstream Consulting$150K15 quarters

Former officials lobbying for it

No lobbyist with a covered position.

Lobbying reports

Filed by
07/17for Q2Upstream ConsultingUnder $5,000
05/04for Q1Upstream ConsultingUnder $5,000
01/30for Q4 2025Upstream ConsultingUnder $5,000
25/10/25for Q3 2025Upstream ConsultingUnder $5,000
25/08/01for Q2 2025Upstream ConsultingUnder $5,000
25/05/05for Q1 2025Upstream ConsultingUnder $5,000
25/02/02for Q4 2024Upstream ConsultingUnder $5,000
24/10/17for Q3 2024Upstream ConsultingUnder $5,000
24/08/20for Q2 2024Upstream ConsultingUnder $5,000
24/05/09for Q1 2024Upstream ConsultingUnder $5,000
24/01/03for Q4 2023Upstream Consulting$30K
23/10/14for Q3 2023Upstream Consulting$30K
23/07/20for Q2 2023Upstream Consulting$30K
23/04/07for Q1 2023Upstream Consulting$30K
23/01/21for Q4 2022Upstream Consulting$30K